Document is current
Any future updates will be listed below
-
Authors
Dou, Lijun
Xu, Zhenxing
Xu, Jielin
Zang, Chengxi
Su, Chang
Pieper, Andrew A.
Leverenz, James B.
Wang, Fei https://orcid.org/0000-0001-9459-9461
Zhu, Xiongwei
Cummings, Jeffrey
Cheng, Feixiong https://orcid.org/0000-0002-1736-2847
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG084250, U01AG073323, R01AG066707, R01AG076448)
- License Information
-
More Information
Article History
Received: 6 August 2024
Accepted: 6 January 2025
First Online: 22 January 2025
Competing interests
: J.C. has provided consultation to Acadia, Acumen, ALZpath, Aprinoia, Artery, Biogen, Biohaven, BioXcel, Bristol-Myers Squib, Eisai, Fosun, GAP Foundation, Janssen, Karuna, Kinoxis, Lighthouse, Lilly, Lundbeck, LSP/eqt, Merck, MoCA Cognition, New Amsterdam, Novo Nordisk, Optoceutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, ReMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, sinaptica, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies. J.C. owns the copyright of the Neuropsychiatric Inventory. J.C. has stocks/options in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, Acumen. J.B.L. has received consulting fees from consulting fees from Vaxxinity, grant support from GE Healthcare and serves on a Data Safety Monitoring Board for Eisai.
